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Monogenic autoinflammatory diseases are a group of hereditary disorders characterized by a clinical and biological
inflammatory syndrome in which there is little or no evidence of autoimmunity. The discovery of the first causative
gene in 1997 was rapidly followed by the identification of many others from the same group. The mutated proteins
can be directly or indirectly involved in the regulation of inflammation. The available literature includes numerous
reviews, which address the principle diseases, but we wanted to focus on the most recent rare syndromes. A
comprehensive review is thus provided, including taxonomic, genetic, and epidemiological data, along with
characteristics defining positive and differential diagnoses and treatment. We believe that this update will assist
physicians in correctly naming their patient’s illness. This is an essential step for the effective and targeted
management of an orphan disease.
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Les maladies autoinflammatoires monogéniques sont un groupe de pathologies héréditaires caractérisées par un
syndrome inflammatoire clinique et biologique, dans lesquelles on ne retrouve pas ou peu de signe
d'autoimmunité. La découverte du premier gène en 1997 a été rapidement suivie par l’identification de nombreux
autres appartenant au même groupe. Les protéines mutées participent directement ou indirectement à la
régulation de l’inflammation. De nombreuses revues balayant les principales entités sont disponibles dans la
littérature, mais nous avons voulu mettre la lumière sur les formes rares les plus récentes. Nous proposons une
revue exhaustive incluant des données taxonomiques, génétiques, épidémiologiques, ainsi que des éléments
cliniques de certitude et différentiels, et de traitement. Nous espérons que cette mise à jour aidera le médecin à
mettre un nom sur la maladie dont souffrent leurs patients atteints de maladie autoinflammatoire, une étape
indispensable pour une prise en charge efficace et ciblée.* Correspondence: isabelle.touitou@inserm.fr
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Autoinflammatory diseases arise from disorders of the
innate immune system [1]. The prototype disease is
familial Mediterranean fever (FMF), which belongs to
the group of hereditary recurrent fevers. Periods of
inflammation are predominantly triggered following
unnoticed proinflammatory signals. The levels of serum
markers of inflammation such as C-reactive protein are
always increased during attacks, however autoantibodies
remain mostly undetectable. Since the discovery in 1997
of the gene responsible for FMF [2,3], dramatic insights
have been gained through establishing the central role
of the inflammasomes by unraveling their components
and interacting cellular partners [4-6]. Subsequent to
the identification of causal mutations in monogenic
autoinflammatory diseases, several sequence variants in
the causative genes were found to act as susceptibility
factors in the more common multifactorial diseases
such as rheumatoid arthritis or multiple sclerosis [7].
More recently, monogenic autoinflammatory disorders
expanded to include the so far-called inflammatory skin
diseases without systemic involvement. Enhanced know-
ledge relating to the critical physiological mechanisms
altered in these diseases fuelled the development of novel,
dramatically effective targeted biological drugs such as
Interleukin-1 inhibitors [8]. As autoinflammatory diseases
are rare, a national referral center nominated by the
French ministry of health was set-up (CeRéMAI; [http://
asso.orpha.net/CEREMAI/EN/index.html]) in order to im-
prove care for patients. This referral center created
Infevers [9] [fmf.igh.cnrs.fr/infevers/], a dedicated online
database for autoinflammatory mutations [9].
This review focuses on monogenic autoinflammatory
diseases identified within the last five years, including
epidemiological and genetic data (Table 1), an exhaustive
description of the corresponding disease name and syno-
nyms where available, OMIM and Orphacode numbers,
main clinical signs and therapeutic approaches (Table 2).
Rare recently recognized monogenic autoinflammatory
diseases
The correct diagnosis of monogenic autoinflammatory
diseases relies on the physicians’ awareness. Due to the
rarity of these disorders, a very low number of cases
are reported. For example, less than five patients with
clear autoinflammatory features and causative mutations
have been published for each of H syndrome [10-13],
Autoinflammation and PLCG2-associated antibody defi-
ciency and Immune Dysregulation syndrome (APLAID)
[14], and RANBP-Type and C3HC4-Type Zinc Finger-
Containing 1 (RBCK1)-related disease [15]. These three
conditions are thus cited in Tables 1 and 2 only. Moreover,
as mutations in these rare conditions have apparently
systemic and pleiotropic effects, the patients’ clinicalspectrum is heterogeneous and not yet completely
delineated. Molecular analysis of the candidate genes
may also fail to detect mutations. Consequently, the
frequency of these diseases is unknown and too little
feedback and data exist on the clinical significance and
penetrance of the variants to ensure adequate genetic
counseling for these patients.
NLRP12 Associated Periodic Syndrome (NAPS12)
This disease is characterized by recurrent periods of fever,
combined with various systemic manifestations such as
myalgia, arthralgia, headaches and skin urticarial-like rash
although some patients may display arthralgia or myalgia
only [16-18]. The most severely affected patients suffer
from neurosensory signs (headache, deafness) [18]. The
inflammatory attacks last 5-10 days and are triggered by
physical exertion or cold exposure. These attacks can be
very disabling in everyday life and can have a major impact
on school attendance or work. The disease appears to be
more active in children and teenagers than in adults.
Treatment is not standardized and no long-term
medication has proven to be effective. Patients with a
mild phenotype may be treated symptomatically with
non-steroidal anti-inflammatory drugs. There is cur-
rently no therapeutic option available for patients with
the most severe phenotype, and long-term treatment
with interleukin (IL)-1 inhibitors (Anakinra, Kineret®)
failed in the two cases tested [19].
The genetic defect of this disease was identified in
2008 [18] as a mutation in the gene encoding NLR pyrin
domain-containing protein 12 (NLRP12) belonging to
the intracellular Nod-like receptor (NLR) family. This
protein is an intracellular sensor of the innate immune
system, that regulates inflammatory processes through
inhibition of nuclear factor kappa B (NF-κB) [18] and
IL1β [16] signaling. NLRP12 mutations are likely re-
sponsible for a loss of protein function resulting in
upregulation of this pro-inflammatory pathway. How-
ever, the exact role of NLRP12 remains unknown. It may
participate in the formation of an NLRP3-independent
inflammasome and be crucial for the recognition of intra-
cellular pathogens. NLRP12 could also play an important
role in the homeostasis of the gut by controlling the
genesis of inflammatory diseases of the gastrointestinal
tract and/or colorectal cancer [20,21]. Two unambigu-
ous mutations, c.850C > T, p.Arg284*; c.2072 + 2dupT,
p.Val635Thrfs*12 [18] as well as two missense substi-
tutions c.1054C > T, p.Arg352Cys [16] and c.882C > G,
p.Asp294Glu [17] were proven pathogenic through
functional studies.
Deficiency of Interleukin 1 Receptor Antagonist (DIRA)
Sterile multifocal osteomyelitis with periostitis and
pustulosis (OMPP) is more commonly referred to as
Table 1 Epidemiology and genetics of rare recently recognized monogenic autoinflammatory diseases
Year of gene
discovery







2008 H Syndrome Histiocytosis
lymphadenopathy plus
syndrome
4 2/2 1 Indian case 12 Recessive SLC29A3 So te Carrier
Fa ily
10q22.1 ND
1 Pakistani case 13
1 Morocan case 10 29 ucleoside
Tr sporter),
M ber 31 Tunisian case 11
2008 NAPS12 NLRP12 Associated Periodic
Syndrome
19 13/6 2 Guadeloupean
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2009 DIRA Deficiency of Interleukin 1
Receptor Antagonist
17 9/8 1 Turkish family 23 Recessive IL1RN In leukin 1 2q13 c.-64_1696del,
p.IL1F9_IL1RNdel
1 Lebanese 22 re ptor antagonist
family 22
2 Dutch families 22 c.213_227del,
p.Asp72_Ile76del
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Table 1 Epidemiology and genetics of rare recently recognized monogenic autoinflammatory diseases (Continued)
2011 DITRA Deficiency of Interleukin 66 26/37 3 Tunisian
families











10 Asian cases 35 c.28C>T,
p.Arg10*
6 Tunisian cases 30




1 Spanish case 9
1 Turkish case 36
1 Iraqi case 36
1 Russian case 37
2012 PSORS2 Psoriasis susceptibility 2 45 24/21 1 European
family











3 German cases 36
PRP Pityriasis Rubra Pilaris 17 9/8 4 Israeli families 41
2012 DSAP Disseminated Superficial
Actinic Porokeratosis
>45 21/16/ND 20 Chinese
families,









40 26/14 22 Japanese
families










3 Hispanic cases 54




1 Japanese case 53
1 Israeli case 54



















Table 1 Epidemiology and genetics of rare recently recognized monogenic autoinflammatory diseases (Continued)
2012 APLAID Autoinflammation, Antibody
deficiency, and Immune
Dysregulation syndrome
2 1/1 1 family of
unknown origin
14 Dominant PLCG2 Phospholipase C,
gamma 2
16q23.3 ND
2012 NA Autoinflammatory syndrome
with pyogenic bacterial
infection and amylopectinosis





* Commonly used disease names as defined in Table 2 ** Genetically confirmed. *** “Family” refers to multiplex families; “Case” refers to sporadic patients **** Approved HUGO.














































































FCAS1 FCAS3 NSAID (IL-1
blockades not
effective)
































































































Table 2 Clinical features of rare recently recognized monogenic autoinflammatory diseases (Continued)






















































































































ND ND ND ND
*Approved OMIM; NA Not assigned yet; ND: too few patients to delineate clear criteria. Commonly used disease names are in bold text.
NSAID: nonsteroidal anti-inflammatory drugs.
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http://www.ojrd.com/content/8/1/162DIRA [22]. DIRA is an early-onset auto-inflammatory
disease that presents with neutrophilic pustular derma-
tosis, periostitis, aseptic multifocal osteomyelitis, and high
acute-phase reactants. Patients develop pustular skin
rashes, gastrointestinal reflux, and multifocal osteomyelitis
during the neonatal period. One patient presented with
early onset intrauterine disease and intrauterine fetal
demise [23]. Massive systemic inflammatory syndrome
resulting in patient death has been described [22]. Other
manifestations include osteopenia, interstitial pneumonia
often causing hypoxemia and dyspnea or localized
ground-glass opacities and areas of atelectasis at chest
computed tomography, vesicular stomatitis, mouth ulcers,
ribs widening, periosteal reaction, joint swelling, cervical
vertebra fusion, hepatosplenomegaly, thrombosis and
vasculopathy [22,24-26]. Skin biopsies show neutrophilic
epidermal and dermal infiltration, concomitant superficial
folliculitis, with subcorneal localization of the pustules.
Differential diagnosis includes other autoinflammatory
conditions especially deficiency of the Interleukin 36
receptor antagonist (DITRA), dermatologic conditions
(infantile pustular psoriasis, tinea, bacterial folliculitis,
scabies, eosinophilic pustular folliculitis, erythema toxicum
neonatorum, transient neonatal pustular melanosis…), and
infectious diseases (arthritis, osteomyelitis).
Antibiotics and conventional disease-modifying anti-
rheumatic drugs including steroids are of limited benefit,
however blocking IL-1 signaling with anakinra dramatic-
ally improved clinical symptoms within days, resolving
osteolytic lesions, normalizing acute-phase reactants,
and permitting appropriate growth [22,24-29]. Patients
with DIRA need to remain on lifelong IL-1 inhibitory
therapy. Previous attempts at stopping or weaning
anakinra have resulted in disease flares.
The disease is caused by mutations of the gene encoding
the protein IL1RA. This protein is a natural antagonist
of the potent proinflammatory interleukins-1 cytokines
and mutations result in over activity of IL-1α as well
as IL-1beta is expected in case of IL-1RA deficiency
Two founder deletions were reported, one Puerto Rican:
c.-64_1696del, p.IL1F9_IL1RNdel [22,24,27], and one
Brazilian: c.213_227del, p.Asp72_Ile76del [25].
Deficiency of IL-36 receptor antagonist (DITRA)
Interleukin-36-receptor antagonist deficiency is a her-
editary auto-inflammatory disease characterized by re-
peated flares of generalized pustular psoriasis (GPP).
The flares include sudden diffuse pustular erythematous
rash associated with high fever, general malaise, sys-
temic inflammation and sometimes ‘geographic tongue’
and nail dystrophy [30]. Organ inflammation such as
cholangitis can occur during the disease course. In most
patients, symptoms develop during childhood though
the age of onset can vary considerably. Neonatal onsethas also been reported. Failure to thrive may occur.
Elevated C-reactive protein serum levels and marked
leukocytosis are constant during disease attacks. Differ-
ential diagnosis includes other causes of GPP, mainly
DIRA [22], in cases where symptoms appear during the
first weeks of life.
There is no established treatment. Topical and oral ste-
roids, vitamin D3, acitretin and anti-TNF-α, are effective.
Our group has recently successfully treated an infant with
DITRA not responding to topical and oral steroids or to
acitretine with anakinra [31].
IL-36 receptor antagonist (IL-36RA) is a natural antag-
onist of IL-36α, IL-36β and IL-36γ, three cytokines be-
longing to the IL-1 family. Mutations result in decreased
IL-36RA antagonistic effects due to a reduction of both
IL-36RA protein stability and affinity for its receptor, the
consequence of which is uncontrolled inflammation
[30,32-37]. The high resulting expression of IL-36R and of
the three agonists in epithelial tissues like skin likely
causes GPP, the main clinical feature in all DITRA pa-
tients. In a recent study, Setta-Kafetzi et al. identified
IL36RN variant alleles in palmarplantar pustulosis and
acrodermatitis continua of hallopeau, two forms of GPP
genetically distinct from psoriasis vulgaris [35].
Among the most frequent genetic alterations are
one Tunisian founder missense mutation: c.80C > T,
p.Leu27Pro1; one European recurrent missense muta-
tion: c.338C > T, p.Ser113Leu2; and one Japanese founder
nonsense mutation: c.28C > T, p.Arg10*3.
Psoriasis susceptibility (PSORS)2 and pityriasis rubra
pilaris (PRP)
Psoriasis is a common and chronic immune-mediated
inflammatory disease of the skin affecting approximately
2% of individuals of European descent with a strong gen-
etic susceptibility [38]. Classic lesions consist of round,
well-circumscribed erythematous plaques covered by a
thick silver scale with a predilection for elbows, knees,
scalp, lumbosacral and anogenital regions. Fingernail
plate involvement includes pitting and distal onycholysis.
Inverse psoriasis (flexural distribution), guttate psoriasis,
pustular or erythrodermic psoriasis are other clinical
variants. Pityriasis rubra pilaris (PRP) is a chronic skin
disorder of abnormal keratinization classified by Griffiths
into five types based on the age of onset and the clinical
features [39]. Familial PRP belongs to the type V group
(atypical juvenile) and accounts for about 5% of all cases.
This chronic skin disorder usually presents at birth or
appears during early childhood. It is characterized by
small keratotic follicular papules forming disseminated
salmon-colored scaly plaques that surround islands
of normal skin, and diffuse red-orange palmoplantar
keratoderma. Lesions typically progress rostral to caudal.
While nails can be dystrophic, pitting of nails is not a
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the clinical features or the responses to treatment are
unusual. Histopathological analysis shows psoriasiform
hyperplasia presenting as acanthosis with elongation of
the rete ridges, parakeratosis and mononuclear cell infil-
trate. Compared to psoriasis, the epidermal hyperplasia in
PRP is more irregular, the granular layer is preserved,
follicular plugging is characteristic and neutrophils in the
stratum corneum are not essential. Differential diagnosis
of psoriasis includes other papulosquamous disorders.
PRP shows clinical features similar to phrynoderma
(vitamin A deficiency), psoriasis, erythrokeratodermia
and other causes of cornification.
Management of psoriasis includes patient education,
topical therapy (corticosteroids, calcineurin inhibitor,
calcipotriene, emollients, keratolytic agents), ultraviolet
light, and systemic therapy (retinoids, methotrexate,
cyclosporine and anti-TNF agents). The treatment of
PRP is often disappointing. Milder cases of the disease
can be treated with emollients, topical corticosteroids,
tazarotene, keratolytic agents or calcineurin inhibitor
whereas systemic retinoids and/or TNFα blocking agents
are required in severe cases.
The prognosis of both disorders is that of most chronic
diseases, with spontaneous remissions and exacerbations.
Arthritis is present in about one fourth of psoriasis
patients, and there is an increased risk of metabolic
syndromes and cardiovascular diseases [40].
Both phenotypes have been associated to CAspase
Recruitment Domain-containing protein 14 (CARD14)
mutations [36,41-43]. CARD14 is an epidermal regulator
of NF-κB transcription factor. Mutations in CARD14 initi-
ate a process that includes inflammatory cell recruitment
by keratinocytes and perpetuate a vicious cycle of epi-
dermal inflammation and regeneration that cause the
abnormal keratinization. More specifically, c.349G > A,
p.Gly117Ser (the most prevalent mutation), and c.413A > C,
p.Glu138Ala (a de novo mutation) were shown to lead to
enhanced NF-κB activation and upregulation of a subset
of psoriasis-associated genes in keratinocytes [43].
Disseminated Superficial Actinic Porokeratosis (DSAP)
This disease described in 1966 by Chernosky [44] repre-
sents the most common form of porokeratosis, a group of
diseases characterized by epidermal cornification with epi-
dermal cell hyperproliferation and premature apoptosis of
keratinocytes. Triggers include ultraviolet light exposure
and immunosuppression. Multiple small (0.5-1 cm) round
and brownish lesions surrounded by a hyperkeratotic rim
develop on sun-exposed areas of the skin particularly on
the lower legs and forearms. Lesions usually appear in
summer and improve or disappear during winter. The dis-
ease usually starts during the third or fourth decades of
life, and rarely affects children. While it is usually benign,squamous cell carcinoma or Bowen’s disease may occa-
sionally develop within the lesions.
Histopathological examination of the skin sampled from
the edge of the peripheral rim characteristically shows an
angulated cornoid lamella and a parakeratotic column
overlying an area of epidermis with an absent or reduced
granular layer [45]. Differential diagnosis includes neoplas-
tic or hyperplastic squamous skin lesions.
Cryotherapy, topical reagents (retinoids, imiquimod, 5-
fluorouracil, keratolytic), electrodessication, laser ablation
or photodynamic therapy are used to destroy the abnor-
mal keratinocyte clones [46].
The mode of inheritance is dominant however many
sporadic cases of porokeratosis have been described [47].
Mutations in the MeValonate Kinase (MVK) gene were
found in DSAP patients [48,49]. The MVK enzyme is in-
volved in the biosynthesis of cholesterol and isoprenoid.
It is also thought to play a role in regulating calcium-
induced keratinocyte differentiation and could protect
keratinocytes from apoptosis induced by type A ultraviolet
radiation. All genetically confirmed patients are of Chinese
origin. Fourteen different mutations have been found,
among which, 10 accounted for one third of the familial
cases. Mutations in this gene were initially demonstrated
as responsible for recessive complete (mevalonic aciduria
[50], OMIM 610377) and incomplete (hyperIgD syndrome
[51,52], OMIM 260920) mevalonate kinase deficiency.
Autoinflammation, LipoDystrophy, and Dermatosis
syndrome (ALDD)
ALDD is a systemic inflammatory condition starting
within the first months of life, and comprising elevated
fever, panniculitis with lipoatrophy, purplish and swol-
len eyelids, arthralgia, developmental retardation, and
increased acute phase reactants [53,54]. Key symptoms
include a persistent fever of >38.5°C, steroid-sensitive
erythema nodosum-like (edematous and purpuric)
plaques, long clubbed fingers, hyperhidrosis, myositis,
hepatosplenomegaly, macroglossia, facial and limbs
lipoatrophy, and developmental (height, weight and
IQ) retardation. Skin biopsies show immature myeloid-
lineage cells with mitoses. Some patients may have
joint contracture, auricular and nasal chondritis, and
calcification of the basal ganglia. Acute cardiovascular
event is the leading cause of death in these patients for
whom life expectancy is notably reduced. Differential
diagnosis includes other autoinflammatory conditions,
in particular Sweet’s syndrome, Still’s disease and Chronic,
Infantile, Neurological, Cutaneous and Articular (CINCA)
syndrome, storage diseases (mucopolysaccharidosis), lupus,
dermatomyositis, laminopathies (progeroid syndromes),
and other interferonopathies like Aicardi Goutieres
syndrome, an interferon type I related disease. Bio-
logical findings include microcytic or normocytic
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amino transferase enzymes, perturbation of glucose
and lipid metabolism (hyperglycemia and glucose in-
tolerance, increased cholesterol and triglycerides), in-
creased erythrocyte sedimentation rate and γ globulins
levels, and some markers of autoimmunity (antinuclear
and anti-neutrophilic cytoplasmic auto-antibodies, lupus
anticoagulant, positive Coombs test).
Management of these patients is by palliative care.
The need for steroids is very high even in combination
with anti IL-1, anti IL-6 or anti-TNF treatments. Drugs
targeting interferon γ are warranted. JAK kinase inhibitors
are currently under clinical trials at the National Institute
of Health, Bethesda, USA [55].
Most (N = 28) of the reported patients carried homo-
zygous mutations in the Proteasome Subunit, Beta-Type,
8 (PSMB8) gene [53,54,56,57]. This gene encodes β5i, a
catalytic subunit of the immunoproteasome, an intracel-
lular protease complex specialized for degradation of
polyubiquitinated proteins. This ubiquitin-proteasome
system degrades unnecessary proteins and regulates the
cell cycle, gene repair and nuclear factor NF-κB activa-
tion [53]. The mutated protein impairs the assembly of
this immunoproteasome. One nonsense (c.405C > A,
p.Cys135*) [54] and five missense mutations of which
two are recurrent (c.224C > T, p.Thr75Met and c.602G > T,
p.Gly201Val) have been reported [9]. As the prognosis is
so severe, prenatal diagnosis can be discussed.
Conclusions
Hereditary recurrent fevers, as well as Majeed syn-
drome, Blau syndrome, and Pyogenic sterile Arthritis,
Pyoderma gangrenosum and Acne (PAPA) syndrome,
have been extensively reviewed since the concept of
autoinflammation was created in 1999 [58]. However,
very little information has been assembled regarding the
phenotype, genetics and epidemiology of the more re-
cently discovered autoinflammatory disorders. Here in
this review, we aimed to offer novel diagnostic options
to those patients for whom a genetic link could not be
established. More than 25 autoinflammatory genes were
listed during the last international conference on auto-
inflammation, Lausanne, 23-26 May, 2013, including at
least five to six new ones in the pipeline. Both pheno-
type and genotype heterogeneity have been described
which further hinders correct diagnosis and highlights
the necessity for a gene and disease nomenclature con-
sensus. A systematic in-depth description of the clinical
features of these patients has been undertaken thanks to
the Eurofever initiative [59,60]. Massively parallel sequen-
cing approaches should help in identifying the causative
gene among those already known or novel genes through
whole exome or genome sequencing. Development of
such innovative genetic diagnostic tools is in progressthrough an International network (I Touitou, personal
communication).
The correct diagnosis of these diseases is essential for
the relevant management of patients affected by rare
autoinflammatory diseases as remarkably effective ther-
apies have been developed recently which have the
potential to avoid the risk of fatal complications such as
amyloidosis, or sensorineural impairment. Rarely empha-
sized yet equally important is being able, even after many
years as in some cases, to name the patient’s disease,
which can be extremely useful from a psychological point
of view.
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